Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies

被引：8
|
作者：
Saleh, Mansoor
Gutierrez, Martin E.
Subbiah, Vivek
Smith, David C.
Asatiani, Ekaterine
Lihou, Christine F.
Zhen, Huiling
Yeleswaram, Swamy
Ji, Tao
Nemunaitis, John
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT111
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies
    Saleh, Mansoor
    Gutierrez, Martin
    Subbiah, Vivek
    Smith, David C.
    Feliz, Luis
    Zhen, Huiling
    Ji, Tao
    Nemunaitis, John
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [2] A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement
    Vannucchi, Alessandro M.
    Patel, Jay L.
    Shomali, William E.
    George, Tracy I.
    Reiter, Andreas
    Rambaldi, Alessandro
    Oh, Stephen
    Usuki, Kensuke
    Harrison, Claire N.
    Veronese, Maria Luisa
    Gilmartin, Aidan
    Zhen, Huiling
    Verstovsek, Srdan
    Oliveira, Natalia
    Gotlib, Jason
    Kiladjian, Jean-Jacques
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S430 - S431
  • [3] A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)
    Gotlib, Jason
    Kiladjian, Jean-Jacques
    Vannucchi, Alessandro
    Rambaldi, Alessandro
    Reiter, Andreas
    Shomali, William
    George, Tracy I.
    Patel, Jay L.
    Colucci, Philomena
    Walker, Chris
    Zhen, Huiling
    Verstovsek, Srdan
    BLOOD, 2021, 138
  • [4] Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement
    Verstovsek, Srdan
    Rambaldi, Alessandro
    Lihou, Christine
    Zhen, Huiling
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S350 - S351
  • [5] Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement
    Verstovsek, Srdan
    Rambaldi, Alessandro
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Hochhaus, Andreas
    CANCER RESEARCH, 2017, 77
  • [6] FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
    Subbiah, Vivek
    Barve, Minal
    Iannotti, Nicholas O.
    Gutierrez, Martin
    Smith, David C.
    Roychowdhury, Sameek
    Papadopoulos, Kyriakos P.
    Mettu, Niharika
    Edenfield, William J.
    Morgensztern, Daniel
    Feliz, Luis
    Lihou, Christine
    Zhen, Huiling
    Saleh, Mansoor
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [7] INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
    Liu, Phillip C. C.
    Koblish, Holly
    Wu, Liangxing
    Bowman, Kevin
    Diamond, Sharon
    DiMatteo, Darlise
    Zhang, Yue
    Hansbury, Michael
    Rupar, Mark
    Wen, Xiaoming
    Collier, Paul
    Feldman, Patricia
    Klabe, Ronald
    Burke, Krista A.
    Soloviev, Maxim
    Gardiner, Christine
    He, Xin
    Volgina, Alla
    Covington, Maryanne
    Ruggeri, Bruce
    Wynn, Richard
    Burn, Timothy C.
    Scherle, Peggy
    Yeleswaram, Swamy
    Yao, Wenqing
    Huber, Reid
    Hollis, Gregory
    PLOS ONE, 2020, 15 (04):
  • [8] Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)
    Verstovsek, Srdan
    Vannucchi, Alessandro M.
    Rambaldi, Alessandro
    Gotlib, Jason R.
    Mead, Adam J.
    Hochhaus, Andreas
    Kiladjian, Jean-Jacques
    Hernandez Boluda, Juan Carlos
    Asatiani, Ekaterine
    Lihou, Christine
    Zhen, Huiling
    Reiter, Andreas
    BLOOD, 2018, 132
  • [9] COMPLETE HEMATOLOGIC AND CYTOGENETIC RESPONSE IN A PATIENT WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 ACTIVATED MYELOPROLIFERATIVE NEOPLASM RECEIVING INCB054828
    Daver, N.
    Subbiah, V.
    Asatiani, E.
    Verstovsek, S.
    HAEMATOLOGICA, 2017, 102 : 554 - 554
  • [10] Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 for metastatic or surgically unresectable urothelial carcinoma harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) alterations
    Shore, Neal D.
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Gupta, Sumati
    CANCER RESEARCH, 2017, 77
12345